EcoDrugPlus

Tyrosine Kinase With Immunoglobulin Like And Egf Like Domains 1

Ensembl ID : ENSSAUG00010022142
Gene Symbol: TIE1
3 Cross references
205 Possible Orthologues:

Tyrosine-Protein Kinase Fyn

Ensembl ID : ENSSAUG00010006431
Gene Symbol: LOC115574182
3 Cross references
196 Possible Orthologues:

Tyrosine-Protein Kinase Jak2-Like

Ensembl ID : ENSSAUG00010019520
Gene Symbol: LOC115592324
3 Cross references
199 Possible Orthologues:

Tyrosine-Protein Kinase Jak2-Like

Ensembl ID : ENSSAUG00010006688
Gene Symbol: LOC115581166
3 Cross references
194 Possible Orthologues:

Tyrosine-Protein Kinase Lyn-Like

Ensembl ID : ENSSAUG00010017383
Gene Symbol: LOC115573339
3 Cross references
195 Possible Orthologues:

Tyrosine-Protein Kinase Yes

Ensembl ID : ENSSAUG00010005434
Gene Symbol: LOC115572918
3 Cross references
206 Possible Orthologues:

Utrophin

Ensembl ID : ENSSAUG00010016677
Gene Symbol: UTRN
1 Cross references
270 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 2

Ensembl ID : ENSSAUG00010013270
Gene Symbol: AKT2
1 Cross references
209 Possible Orthologues:

Vascular Endothelial Growth Factor A-A-Like

Ensembl ID : ENSSAUG00010018232
Gene Symbol: LOC115574072
3 Cross references
201 Possible Orthologues:

Vascular Endothelial Growth Factor A-A-Like

Ensembl ID : ENSSAUG00010002293
Gene Symbol: LOC115567020
3 Cross references
181 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSSAUG00010000414
Gene Symbol: VDR
3 Cross references
388 Possible Orthologues:

Vitamin D3 Receptor B

Ensembl ID : ENSSAUG00010019658
Gene Symbol: LOC115583480
3 Cross references
392 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).